Amgen’s injectable drug for Rheumatoid Arthritis, Enbrel, was patented in 1998, and the patent has just been extended to 2029 (for reasons IDK). Subject to vigorous appeals in US courts.
Enbrel earned Amgen $1.3 Billion in Q2 alone this year. Average cost - over US$2700 PER MONTH.
Then think about the OA market compared to the RA market......
- Forums
- ASX - By Stock
- PAR
- research reports and media
research reports and media, page-55
-
- There are more pages in this discussion • 4,374 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PAR (ASX) to my watchlist
(20min delay)
|
|||||
Last
24.0¢ |
Change
-0.015(5.88%) |
Mkt cap ! $84.05M |
Open | High | Low | Value | Volume |
25.5¢ | 26.5¢ | 24.0¢ | $167.2K | 671.5K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 108741 | 24.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
25.5¢ | 9700 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
3 | 108741 | 0.240 |
4 | 64258 | 0.235 |
8 | 113649 | 0.230 |
5 | 71572 | 0.225 |
5 | 55537 | 0.220 |
Price($) | Vol. | No. |
---|---|---|
0.255 | 1600 | 1 |
0.260 | 62000 | 2 |
0.265 | 66950 | 4 |
0.270 | 35288 | 4 |
0.275 | 23636 | 3 |
Last trade - 16.10pm 13/09/2024 (20 minute delay) ? |
Featured News
PAR (ASX) Chart |
The Watchlist
LPM
LITHIUM PLUS MINERALS LTD.
Simon Kidston, Non--Executive Director
Simon Kidston
Non--Executive Director
SPONSORED BY The Market Online